Canopy Immuno-Therapeutics

A stealth mode biotech company engaged in the development of novel immunotherapeutic approach for autoimmunity and life-threatening allergy. DEMMUNIZATION™ trademark registration is intended to cover the categories of pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases and disorders; Pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases by eliminating specific lymphocytes lineages or modulating the immune response using a variety of organic compounds and recombinant proteins; Pharmaceutical preparations and substances that modulate the immune system by recombinant proteins that contain a targeting moiety and an effector moiety to eliminate specific lymphocytes lineages and attenuate or block the antibody creation and antigen specific immune response in autoimmune, Allergic and inflammatory diseases; Pharmaceutical preparations and substances that modulate the immune system by recombinant proteins that contain a targeting moiety and an effector moiety to eliminate specific lymphocytes lineages and attenuate or block the creation of the antibodies IgG, IgE or IgA and antigen specific immune response in autoimmune, allergic and inflammatory diseases; Pharmaceutical preparations and substances with potential immunomodulation activity to treat under and over responsiveness of the immune system. REVERSE IMMUNIZATION™ trademark registration is intended to cover the categories of pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases and disorders; Pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases by eliminating specific lymphocytes lineages or modulating the immune response using a variety of organic compounds and recombinant proteins; Pharmaceutical preparations and substances that modulate the immune system by recombinant proteins that contain a targeting moiety and an effector moiety to eliminate specific lymphocytes lineages and attenuate or block the antibody creation and antigen specific immune response in autoimmune, Allergic and inflammatory diseases; Pharmaceutical preparations and substances that modulate the immune system by recombinant proteins that contain a targeting moiety and an effector moiety to eliminate specific lymphocytes lineages and attenuate or block the creation of the antibodies IgG, IgE or IgA and antigen specific immune response in autoimmune, allergic and inflammatory diseases; Pharmaceutical preparations and substances with potential immunomodulation activity to treat under and over responsiveness of the immune system.